Cumulative Radiation Exposures from CT Screening and Surveillance Strategies for von Hippel-Lindau-associated Solid Pancreatic Tumors.


Journal

Radiology
ISSN: 1527-1315
Titre abrégé: Radiology
Pays: United States
ID NLM: 0401260

Informations de publication

Date de publication:
01 2019
Historique:
pubmed: 10 10 2018
medline: 12 10 2019
entrez: 10 10 2018
Statut: ppublish

Résumé

Purpose To assess the potential ionizing radiation exposure from CT scans for both screening and surveillance of patients with von Hippel-Lindau (VHL) syndrome. Materials and Methods For this retrospective study, abdomen-pelvic (AP) and chest-abdomen-pelvic (CAP) CT scans were performed with either a three-phase (n = 1242) or a dual-energy virtual noncontrast protocol (VNC; n = 149) in 747 patients with VHL syndrome in the National Institutes of Health Clinical Center between 2009 and 2015 (mean age, 47.6 years ± 14.6 [standard deviation]; age range, 12-83 years; 320 women [42.8%]). CT scanning parameters for patients with pancreatic neuroendocrine tumors (PNETs; 124 patients and 381 scans) were compared between a tumor diameter-based surveillance protocol and a VHL genotype and tumor diameter-based algorithm (a tailored algorithm) developed by three VHL clinicians. Organ and lifetime radiation doses were estimated by two radiologists and five radiation scientists. Cumulative radiation doses were compared between the PNET surveillance algorithms by analyses of variance, and a two-tailed P value less than .05 indicated statistical significance. Results Median cumulative colon doses for annual CAP and AP CT scans from age 15 to 40 years ranged from 0.34 Gy (5th-95th percentiles, 0.18-0.75; dual-energy VNC CT) to 0.89 Gy (5th-95th percentiles, 0.42-1.0; three-phase CT). For the current PNET surveillance protocol, the cumulative effective radiation dose from age 40 to 65 years was 682 mSv (tumors < 1.2 cm) and 2125 mSv (tumors > 3 cm). The tailored algorithm could halve these doses for patients with initial tumor diameter less than 1.2 cm (P < .001). Conclusion CT screening of patients with von Hippel-Lindau syndrome can lead to substantial radiation exposures, even with dual-energy virtual noncontrast CT. A genome and tumor diameter-based algorithm for pancreatic neuroendocrine tumor surveillance may potentially reduce lifetime radiation exposure. © RSNA, 2018 Online supplemental material is available for this article.

Identifiants

pubmed: 30299237
doi: 10.1148/radiol.2018180687
pmc: PMC6312431
doi:

Types de publication

Journal Article Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

116-124

Références

J Med Genet. 2017 Jan;54(1):11-18
pubmed: 27539272
Eur J Hum Genet. 2011 Jun;19(6):617-23
pubmed: 21386872
Science. 1993 May 28;260(5112):1317-20
pubmed: 8493574
Nat Rev Clin Oncol. 2016 Sep;13(9):537-49
pubmed: 27030075
Phys Med Biol. 2010 Jan 21;55(2):339-63
pubmed: 20019401
J Radiol Prot. 2015 Dec;35(4):891-909
pubmed: 26609995
Br J Radiol. 2017 Dec;90(1080):20170411
pubmed: 28936888
Radiographics. 2008 Jan-Feb;28(1):65-79; quiz 323
pubmed: 18203931
Lancet. 2003 Jun 14;361(9374):2059-67
pubmed: 12814730
Endocr Relat Cancer. 2013 Dec 20;21(1):63-71
pubmed: 24132471
Clin Radiol. 2009 Jun;64(6):589-600
pubmed: 19414081
Dan Med J. 2013 Dec;60(12):B4763
pubmed: 24355456
AJR Am J Roentgenol. 2003 Oct;181(4):987-92
pubmed: 14500214
Ann Surg. 2015 Aug;262(2):384-8
pubmed: 25185468
Tomography. 2017 Jun;3(2):114-122
pubmed: 28856247
CA Cancer J Clin. 2012 Mar-Apr;62(2):75-100
pubmed: 22307864
Pediatr Radiol. 2009 Feb;39 Suppl 1:S27-31
pubmed: 19083227
Eur J Radiol. 2012 May;81(5):e746-9
pubmed: 22386133
Radiology. 2000 Feb;214(2):483-90
pubmed: 10671597
Lancet. 2012 Aug 4;380(9840):499-505
pubmed: 22681860
Radiat Prot Dosimetry. 2017 Aug 1;175(4):482-492
pubmed: 28096313
Semin Radiat Oncol. 2010 Jan;20(1):67-78
pubmed: 19959033
Neuroendocrinology. 2017 Mar 30;105(3):212-244
pubmed: 28355596
J Clin Oncol. 2016 Jun 20;34(18):2172-81
pubmed: 27114602
Radiat Res. 1991 Feb;125(2):214-22
pubmed: 1996380
JAMA Oncol. 2018 Jan 1;4(1):124-126
pubmed: 29075773
AJR Am J Roentgenol. 2017 Jun;208(6):1185-1192
pubmed: 28301210
Surgery. 2011 Dec;150(6):1122-8
pubmed: 22136831
Radiographics. 2018 May-Jun;38(3):849-866
pubmed: 29601266
Environ Health Perspect. 2012 Nov;120(11):1503-11
pubmed: 22728254

Auteurs

Amit Tirosh (A)

From the Neuroendocrine Tumors Service, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel 52621 (A.T.); Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (A.T.); Division of Cancer Epidemiology and Genetics (N.J., C. Lee, A.B.d.G.), Department of Radiology and Imaging Sciences (L.R.F., J.Y., W.K., A.M.), and Urologic Oncology Branch (C. Leite, W.M.L.), National Cancer Institute, National Institutes of Health, Bethesda, Md; Centre for Research in Epidemiology and Population Health (CESP), INSERM U1018, Villejuif, France (N.J.); and Department of Surgery and Stanford Cancer Institute, Stanford University, Stanford, Calif (E.K.).

Neige Journy (N)

From the Neuroendocrine Tumors Service, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel 52621 (A.T.); Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (A.T.); Division of Cancer Epidemiology and Genetics (N.J., C. Lee, A.B.d.G.), Department of Radiology and Imaging Sciences (L.R.F., J.Y., W.K., A.M.), and Urologic Oncology Branch (C. Leite, W.M.L.), National Cancer Institute, National Institutes of Health, Bethesda, Md; Centre for Research in Epidemiology and Population Health (CESP), INSERM U1018, Villejuif, France (N.J.); and Department of Surgery and Stanford Cancer Institute, Stanford University, Stanford, Calif (E.K.).

Les R Folio (LR)

From the Neuroendocrine Tumors Service, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel 52621 (A.T.); Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (A.T.); Division of Cancer Epidemiology and Genetics (N.J., C. Lee, A.B.d.G.), Department of Radiology and Imaging Sciences (L.R.F., J.Y., W.K., A.M.), and Urologic Oncology Branch (C. Leite, W.M.L.), National Cancer Institute, National Institutes of Health, Bethesda, Md; Centre for Research in Epidemiology and Population Health (CESP), INSERM U1018, Villejuif, France (N.J.); and Department of Surgery and Stanford Cancer Institute, Stanford University, Stanford, Calif (E.K.).

Choonsik Lee (C)

From the Neuroendocrine Tumors Service, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel 52621 (A.T.); Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (A.T.); Division of Cancer Epidemiology and Genetics (N.J., C. Lee, A.B.d.G.), Department of Radiology and Imaging Sciences (L.R.F., J.Y., W.K., A.M.), and Urologic Oncology Branch (C. Leite, W.M.L.), National Cancer Institute, National Institutes of Health, Bethesda, Md; Centre for Research in Epidemiology and Population Health (CESP), INSERM U1018, Villejuif, France (N.J.); and Department of Surgery and Stanford Cancer Institute, Stanford University, Stanford, Calif (E.K.).

Christiane Leite (C)

From the Neuroendocrine Tumors Service, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel 52621 (A.T.); Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (A.T.); Division of Cancer Epidemiology and Genetics (N.J., C. Lee, A.B.d.G.), Department of Radiology and Imaging Sciences (L.R.F., J.Y., W.K., A.M.), and Urologic Oncology Branch (C. Leite, W.M.L.), National Cancer Institute, National Institutes of Health, Bethesda, Md; Centre for Research in Epidemiology and Population Health (CESP), INSERM U1018, Villejuif, France (N.J.); and Department of Surgery and Stanford Cancer Institute, Stanford University, Stanford, Calif (E.K.).

Jianhua Yao (J)

From the Neuroendocrine Tumors Service, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel 52621 (A.T.); Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (A.T.); Division of Cancer Epidemiology and Genetics (N.J., C. Lee, A.B.d.G.), Department of Radiology and Imaging Sciences (L.R.F., J.Y., W.K., A.M.), and Urologic Oncology Branch (C. Leite, W.M.L.), National Cancer Institute, National Institutes of Health, Bethesda, Md; Centre for Research in Epidemiology and Population Health (CESP), INSERM U1018, Villejuif, France (N.J.); and Department of Surgery and Stanford Cancer Institute, Stanford University, Stanford, Calif (E.K.).

William Kovacs (W)

From the Neuroendocrine Tumors Service, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel 52621 (A.T.); Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (A.T.); Division of Cancer Epidemiology and Genetics (N.J., C. Lee, A.B.d.G.), Department of Radiology and Imaging Sciences (L.R.F., J.Y., W.K., A.M.), and Urologic Oncology Branch (C. Leite, W.M.L.), National Cancer Institute, National Institutes of Health, Bethesda, Md; Centre for Research in Epidemiology and Population Health (CESP), INSERM U1018, Villejuif, France (N.J.); and Department of Surgery and Stanford Cancer Institute, Stanford University, Stanford, Calif (E.K.).

W Marston Linehan (WM)

From the Neuroendocrine Tumors Service, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel 52621 (A.T.); Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (A.T.); Division of Cancer Epidemiology and Genetics (N.J., C. Lee, A.B.d.G.), Department of Radiology and Imaging Sciences (L.R.F., J.Y., W.K., A.M.), and Urologic Oncology Branch (C. Leite, W.M.L.), National Cancer Institute, National Institutes of Health, Bethesda, Md; Centre for Research in Epidemiology and Population Health (CESP), INSERM U1018, Villejuif, France (N.J.); and Department of Surgery and Stanford Cancer Institute, Stanford University, Stanford, Calif (E.K.).

Ashkan Malayeri (A)

From the Neuroendocrine Tumors Service, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel 52621 (A.T.); Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (A.T.); Division of Cancer Epidemiology and Genetics (N.J., C. Lee, A.B.d.G.), Department of Radiology and Imaging Sciences (L.R.F., J.Y., W.K., A.M.), and Urologic Oncology Branch (C. Leite, W.M.L.), National Cancer Institute, National Institutes of Health, Bethesda, Md; Centre for Research in Epidemiology and Population Health (CESP), INSERM U1018, Villejuif, France (N.J.); and Department of Surgery and Stanford Cancer Institute, Stanford University, Stanford, Calif (E.K.).

Electron Kebebew (E)

From the Neuroendocrine Tumors Service, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel 52621 (A.T.); Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (A.T.); Division of Cancer Epidemiology and Genetics (N.J., C. Lee, A.B.d.G.), Department of Radiology and Imaging Sciences (L.R.F., J.Y., W.K., A.M.), and Urologic Oncology Branch (C. Leite, W.M.L.), National Cancer Institute, National Institutes of Health, Bethesda, Md; Centre for Research in Epidemiology and Population Health (CESP), INSERM U1018, Villejuif, France (N.J.); and Department of Surgery and Stanford Cancer Institute, Stanford University, Stanford, Calif (E.K.).

Amy Berrington de González (A)

From the Neuroendocrine Tumors Service, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel 52621 (A.T.); Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (A.T.); Division of Cancer Epidemiology and Genetics (N.J., C. Lee, A.B.d.G.), Department of Radiology and Imaging Sciences (L.R.F., J.Y., W.K., A.M.), and Urologic Oncology Branch (C. Leite, W.M.L.), National Cancer Institute, National Institutes of Health, Bethesda, Md; Centre for Research in Epidemiology and Population Health (CESP), INSERM U1018, Villejuif, France (N.J.); and Department of Surgery and Stanford Cancer Institute, Stanford University, Stanford, Calif (E.K.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH